# Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

Source: https://onco.cc/trials/nct05256290/  
OnCo record `nct05256290` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Silevertinib in non-small-cell lung cancer and small-cell lung cancer, run by Black Diamond Therapeutics, Inc., active and no longer recruiting.

## Summary

Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations is a phase 1/2 interventional study registered as NCT05256290 by Black Diamond Therapeutics, Inc., with 200 participants planned, started 2022-03-31 and due to reach its primary completion in 2025-11-03. Interventions recorded: silevertinib (BDTX-1535) monotherapy. Conditions listed: Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05256290
- Phase: 1/2
- Setting: A Phase 1/2 Study to Assess BDTX-1535, an Oral EGFR Inhibitor, in Patients With Glioblastoma or Non-Small Cell Lung Cancer
- Sponsor: Black Diamond Therapeutics, Inc.
- Enrolled: 200

## Sources

- ClinicalTrials.gov NCT05256290: https://clinicaltrials.gov/study/NCT05256290

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Silevertinib](https://onco.cc/drugs/silevertinib/)
- companies: [Black Diamond Therapeutics](https://onco.cc/companies/black-diamond-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct05256290.json